HRP20230075T1 - Čvrsti pripravci namijenjeni oralnoj primjeni - Google Patents
Čvrsti pripravci namijenjeni oralnoj primjeni Download PDFInfo
- Publication number
- HRP20230075T1 HRP20230075T1 HRP20230075TT HRP20230075T HRP20230075T1 HR P20230075 T1 HRP20230075 T1 HR P20230075T1 HR P20230075T T HRP20230075T T HR P20230075TT HR P20230075 T HRP20230075 T HR P20230075T HR P20230075 T1 HRP20230075 T1 HR P20230075T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethoxy
- acetyl
- amino
- preparation
- glp
- Prior art date
Links
- 239000008247 solid mixture Substances 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 34
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 16
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 7
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 4
- 229960003834 dapagliflozin Drugs 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 4-carboxyphenoxy Chemical group 0.000 claims 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 2
- 229950011186 semaglutide Drugs 0.000 claims 2
- 108010060325 semaglutide Proteins 0.000 claims 2
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (15)
1. Čvrsti pripravak namijenjen oralnoj primjena, naznačen time što sadrži derivat GLP-1 i dapagliflozin, gdje se navedeni derivat GLP-1 bira iz skupine koju čine
a. semaglutid,
b. Nε26-{2-[2-(2-{2-[2-(2-{(S)-4-karboksi-4-[10-(4-karboksifenoksi)dekanoilamino]butirilamino}etoksi)etoksi]acetilamino}etoksi)etoksi]acetil},Nε37-{2-[2-(2-{2-[2-(2-{(S)-4-karboksi-4-[10-(4-karboksifenoksi)dekanoilamino]butirilamino}etoksi)etoksi]acetilamino}etoksi)etoksi]acetil}-[Aib8,Arg34,Lys37]GLP-1(7-37)-peptid
[image]
c. Nε27-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[10-(4-karboksifenoksi)dekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil],Nε36-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[10-(4-karboksifenoksi)dekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil]-[Aib8,Glu22,Arg26,Lys27,Glu30,Arg34,Lys36]-GLP-1-(7-37)-peptidil-Glu-Gly
[image]
d. Nε36-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[11-(4-karboksifenoksi)undekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil],Nε37-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[11-(4-karboksifenoksi)undekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1-(7-37)-peptid
[image]
e. Nε36-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[11-(4-karboksifenoksi)undekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil],Nε37-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[11-(4-karboksifenoksi)undekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil]-[Aib8,Arg26,Arg34,Lys36,Lys37]-GLP-1-(7-37)-peptid
[image]
te
f. Nε36-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[10-(3-karboksifenoksi)dekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil],Nε37-[2-[2-[2-[[2-[2-[2-[[(4S)-4-karboksi-4-[10-(3-karboksifenoksi)dekanoilamino]butanoil]amino]etoksi]etoksi]acetil]amino]etoksi]etoksi]acetil]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1-(7-37)-peptid
[image]
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni derivat GLP-1 semaglutid.
3. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni derivat GLP-1 Spoj B.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak dodatno sadrži sredstvo za poboljšavanje apsorpcije.
5. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeno sredstvo za poboljšavanje apsorpcije sol NAC.
6. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeno sredstvo za poboljšavanje apsorpcije SNAC.
7. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni derivat GLP-1 i/ili dapagliflozin u obliku farmaceutski prihvatljive soli, estera ili solvata.
8. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak sadrži 5-300 mg dapagliflozina, 20-800 mg soli NAC, primjerice SNAC, te izborno 0,1-100 mg derivata GLP-1.
9. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što doziranje navedenog dapagliflozina je 0,5-50 mg dnevno, a doziranje navedenog derivata GLP-1 je 0,1-100 mg dnevno.
10. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak sadrži jedno ili više dodatnih farmaceutski prihvatljivih pomoćnih sredstava.
11. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni pripravak u obliku tablete, kapsule ili vrećice.
12. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u medicini.
13. Pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u liječenju dijabetesa tipa 2.
14. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 12 ili 13, naznačen time što je primijenjeno doziranje navedenog pripravka u rasponu od 200-1000 mg.
15. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 12-14, naznačen time što se navedeni pripravak primjenjuje jednom dnevno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17175131 | 2017-06-09 | ||
| EP18730344.1A EP3634468B1 (en) | 2017-06-09 | 2018-06-11 | Solid compositions for oral administration |
| PCT/EP2018/065266 WO2018224689A2 (en) | 2017-06-09 | 2018-06-11 | Solid compositions for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230075T1 true HRP20230075T1 (hr) | 2023-03-17 |
Family
ID=59070439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230075TT HRP20230075T1 (hr) | 2017-06-09 | 2018-06-11 | Čvrsti pripravci namijenjeni oralnoj primjeni |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11167014B2 (hr) |
| EP (1) | EP3634468B1 (hr) |
| JP (1) | JP7239495B2 (hr) |
| KR (1) | KR20200015564A (hr) |
| CN (1) | CN110769846A (hr) |
| AR (1) | AR112015A1 (hr) |
| AU (1) | AU2018280875A1 (hr) |
| BR (1) | BR112019025769A2 (hr) |
| CA (1) | CA3064677A1 (hr) |
| CL (1) | CL2019003402A1 (hr) |
| CO (1) | CO2019013047A2 (hr) |
| DK (1) | DK3634468T3 (hr) |
| ES (1) | ES2938050T3 (hr) |
| FI (1) | FI3634468T3 (hr) |
| HR (1) | HRP20230075T1 (hr) |
| HU (1) | HUE060962T2 (hr) |
| IL (1) | IL270812B2 (hr) |
| MA (1) | MA49253A (hr) |
| MX (1) | MX2019013965A (hr) |
| MY (1) | MY197488A (hr) |
| PE (1) | PE20200606A1 (hr) |
| PH (1) | PH12019550249A1 (hr) |
| PL (1) | PL3634468T3 (hr) |
| PT (1) | PT3634468T (hr) |
| RS (1) | RS64045B1 (hr) |
| SI (1) | SI3634468T1 (hr) |
| TW (1) | TWI797133B (hr) |
| WO (1) | WO2018224689A2 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
| MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| KR102376009B1 (ko) * | 2018-12-21 | 2022-03-18 | (주)휴온스 | 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물 |
| WO2021023811A1 (en) * | 2019-08-07 | 2021-02-11 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| US20220395559A1 (en) * | 2019-11-07 | 2022-12-15 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| WO2023065231A1 (en) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
| WO2023123063A1 (en) * | 2021-12-29 | 2023-07-06 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery |
| EP4299052A1 (en) * | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| CN114984191B (zh) * | 2022-07-04 | 2022-10-25 | 北京惠之衡生物科技有限公司 | 一种多肽类药物口服递送组合物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| ATE309197T1 (de) | 1999-02-05 | 2005-11-15 | Emisphere Tech Inc | Verfahren zur herstellung alkylierter salicylamide |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| KR20080102395A (ko) | 2006-02-15 | 2008-11-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법 |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| JP2010528023A (ja) | 2007-05-18 | 2010-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｓｇｌｔ２阻害剤の結晶構造およびその製造方法 |
| CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| US8871264B2 (en) | 2009-11-13 | 2014-10-28 | Astrazeneca Ab | Immediate release tablet formulations |
| TWI484974B (zh) | 2009-12-16 | 2015-05-21 | Novo Nordisk As | 雙重醯化ｇｌｐ－１衍生物 |
| PL2651398T3 (pl) * | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP3225631B1 (en) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP2747563A4 (en) | 2011-08-26 | 2015-06-24 | Aegis Therapeutics Llc | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS |
| ES2965469T3 (es) | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
| ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
| HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
| JP6517690B2 (ja) * | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| EP2976096B1 (en) | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| EP3129041B1 (en) | 2014-04-07 | 2019-06-12 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2017004623A1 (en) * | 2015-07-02 | 2017-01-05 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP7193455B2 (ja) | 2016-11-28 | 2022-12-20 | ノヴォ ノルディスク アー／エス | 心血管状態におけるインスリンデグルデク |
| CN110099719A (zh) | 2016-11-28 | 2019-08-06 | 诺和诺德股份有限公司 | 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素 |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| WO2021023811A1 (en) * | 2019-08-07 | 2021-02-11 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
-
2018
- 2018-06-08 AR ARP180101556A patent/AR112015A1/es unknown
- 2018-06-08 TW TW107119869A patent/TWI797133B/zh active
- 2018-06-11 WO PCT/EP2018/065266 patent/WO2018224689A2/en active Application Filing
- 2018-06-11 DK DK18730344.1T patent/DK3634468T3/da active
- 2018-06-11 EP EP18730344.1A patent/EP3634468B1/en active Active
- 2018-06-11 CA CA3064677A patent/CA3064677A1/en not_active Withdrawn
- 2018-06-11 US US16/620,363 patent/US11167014B2/en active Active
- 2018-06-11 CN CN201880038208.9A patent/CN110769846A/zh not_active Withdrawn
- 2018-06-11 JP JP2019567972A patent/JP7239495B2/ja active Active
- 2018-06-11 AU AU2018280875A patent/AU2018280875A1/en not_active Withdrawn
- 2018-06-11 RS RS20230103A patent/RS64045B1/sr unknown
- 2018-06-11 HU HUE18730344A patent/HUE060962T2/hu unknown
- 2018-06-11 MA MA049253A patent/MA49253A/fr unknown
- 2018-06-11 PE PE2019002460A patent/PE20200606A1/es unknown
- 2018-06-11 KR KR1020197037131A patent/KR20200015564A/ko unknown
- 2018-06-11 HR HRP20230075TT patent/HRP20230075T1/hr unknown
- 2018-06-11 ES ES18730344T patent/ES2938050T3/es active Active
- 2018-06-11 MX MX2019013965A patent/MX2019013965A/es unknown
- 2018-06-11 PT PT187303441T patent/PT3634468T/pt unknown
- 2018-06-11 MY MYPI2019006851A patent/MY197488A/en unknown
- 2018-06-11 BR BR112019025769-1A patent/BR112019025769A2/pt not_active Application Discontinuation
- 2018-06-11 SI SI201830839T patent/SI3634468T1/sl unknown
- 2018-06-11 PL PL18730344.1T patent/PL3634468T3/pl unknown
- 2018-06-11 IL IL270812A patent/IL270812B2/en unknown
- 2018-06-11 FI FIEP18730344.1T patent/FI3634468T3/fi active
-
2019
- 2019-11-22 CO CONC2019/0013047A patent/CO2019013047A2/es unknown
- 2019-11-22 CL CL2019003402A patent/CL2019003402A1/es unknown
- 2019-11-22 PH PH12019550249A patent/PH12019550249A1/en unknown
-
2021
- 2021-10-08 US US17/496,831 patent/US20220016216A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230075T1 (hr) | Čvrsti pripravci namijenjeni oralnoj primjeni | |
| HRP20231205T1 (hr) | Čvrsti pripravci koji sadrže agonist glp-1, sol n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline i mazivo | |
| JP2015515459A5 (hr) | ||
| JP2016519128A5 (hr) | ||
| JP2020058871A5 (hr) | ||
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20211415T1 (hr) | Brzodjelujući pripravci inzulina | |
| US20150273069A1 (en) | Fatty acid acylated amino acids for oral peptide delivery | |
| MX2023005223A (es) | Estructuras de permanencia, y metodos relacionados. | |
| JP2013522194A5 (hr) | ||
| AR045076A1 (es) | Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se | |
| RU2016151697A (ru) | Расправляемая удерживаемая в желудке лекарственная форма | |
| ECSP17085659A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| EA200301004A1 (ru) | Восстанавливаемая композиция для парентерального введения, содержащая ингибитор cox-2 (циклооксигеназа-2) | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| WO2019108580A8 (en) | Gastric resident electronics | |
| AR105184A1 (es) | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos | |
| MX2017002596A (es) | Composiciones y métodos farmacéuticos. | |
| JP2017512194A5 (hr) | ||
| MXPA06008241A (es) | Composicion dermatologica de gel suave. | |
| JP2017507142A5 (hr) | ||
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| AU2015201581B2 (en) | Pharmaceutical Compositions and Related Methods of Delivery | |
| TH2001004196A (th) | องค์ประกอบที่เป็นของแข็งที่ประกอบรวมด้วย glp-1 อะโกนิสต์,เกลือของกรด n-(8-(2-ไฮดรอกซีเบนโซอิล)อะมิโน)คาไพรลิก และสารหล่อลื่น | |
| RU2020118258A (ru) | Режим дозирования эдасалонексента при лечении мышечной дистрофии |